David Bond, M.D., Ph.D.

Associate Professor, Department of Psychiatry

E-MAIL: [email protected]

Research Interests:

Bipolar disorder (BD) is a neuropsychiatric illness in which people experience episodes of depression and episodes of abnormally elevated mood and energy, referred to as manic episodes. BD affects over 10 million Americans. Most affected individuals respond well to treatment, have relatively few mood episodes, and function well in their day-to-day lives. However, approximately one-third do not. These individuals have a deteriorating course with increasingly frequent mood episodes, treatment refractoriness, and high rates of disability. My research program is dedicated to identifying factors that promote good clinical outcomes in people with BD, and understanding how they interact with the neurobiological substrate of BD to influence brain illness severity. Current research projects include:

1) Investigating biological and clinical factors that enable the early and accurate diagnosis of BD. This is critical because early diagnosis and early optimization of treatment are among the strongest predictors of good clinical outcomes. Unfortunately, over 60% of people with BD are initially misdiagnosed, and they frequently go 6-10 years before receiving the correct diagnosis. We are currently investigating whether a proteomic assay which measures the serum levels of 18 blood proteins can correctly distinguish between bipolar disorder and related psychiatric illnesses in people who present for psychiatric care. We also use causal discovery modelling to investigate symptom networks in mania and bipolar depression to better understand the phenotype of BD.

2) Investigating cardiovascular risk factors (CVRFs) as predictors of psychiatric illness course and brain health in BD. CVRFs such as obesity and smoking are the strongest determinants of morbidity and mortality worldwide. There is growing awareness that they negatively impact brain health and hasten the onset and progression of neuropsychiatric illnesses. We previously found that the structural and chemical brain changes characteristic of BD were more pronounced in obese BD patients than normal-weight BD patients, and progressed more rapidly in patients who experienced additional weight gain. These studies suggested a potential neurobiological explanation for the link between CVRFs and a worse clinical illness course. We are currently using magnetic resonance brain imaging to investigate whether the brain changes characteristic of BD are also more pronounced in BD smokers than BD non-smokers. Taken together, these studies will lay the theoretical groundwork to support planned investigations of whether weight loss and smoking cessation interventions improve clinical outcomes and slow brain illness progression in BD.

Selected Publications:

(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)

  • Chinna Meyyappan A, Sgarbossa C, Vazquez G, Bond DJ, Müller DJ, Milev R. The safety and efficacy of microbial ecosystem therapeutic-2 in people with major depression: Protocol for a phase 2, double-blind, placebo-vontrolled study. JMIR Res Protoc. 2021 Sep 22;10(9):e31439.
  • Bond DJ, Silveira LE, Torres IJ, Lam RW, Yatham LN. Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. Psychol Med. 2021 Mar 12:1-9.
  • Bond DJ, Torres IJ, Lam RW, Yatham LN. Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder. J Affect Disord. 2020 Jun 1;270:30-35.
  • Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ,  Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O’Donovan C, McIntosh D, Lam RW, Vasquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT)/International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170. 
  • Yatham LN, Sossi V, Ding Y-S, Vafai N, Lam RW, Bond DJ, Puyat J. Positron emission tomography study of norepinephrine transporter occupancy and its correlation with symptom response in depressed patients treated with quetiapine XR. Int J Neuropsychopharmacol. 2018;21:108-113.
  • Bond DJ, Torres IJ, Lee SS, Kozicky JM, Silveira LE, Dhanoa T, Lam RW, Yatham LN. Lower cognitive functioning as a predictor of weight gain in early-stage bipolar disorder patients and healthy young adults: A 12-month study. Acta Psychiatr Scand. 2017;135:239-249.
  • Bond DJ, Silveira LE, MacMillan EL, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN. Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. Transl Psychiatry. 2017;7:e1071.
  • Bond DJ, Andreazza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, Young LT, Lam RW, Yatham LN. 2017. A longitudinal study of the relationships between mood symptoms, body mass index, and serum adipokines in bipolar disorder. J Clin Psychiatry  2017;78:441-448.
  • Silveira LE, Bond DJ, MacMillan EL, Kozicky JM, Muralidharan K, Bücker J, Rosa AR, Kapczinski F, Yatham LN. Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: a prospective 12-month proton magnetic resonance spectroscopy study. Aust NZ J Psychiatry  2017;51:65-74.
  • McGirr A, Berlim MT, Bond DJ, Chan PY, Yatham LN, Lam RW. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psych.. 2017;210:403-407.
  • Schulz SC, Overgaard S, Bond DJ, Kaldate R. Assessment of proteomic measures across serious psychiatric illness. Clin Schizophr Relat Psychoses. 2017;11:103-112.
  • Nassan M, Yun-Fang J, Jenkins G, Colby C, Feeder S, Choi DS, Veldic M, McElroy SL, Bond DJ, Weinshilboum R, Biernacka JM, and Frye MA. Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: applications of a proteomic informed genomic approach. J Psychiatry Res.  2017;95:208-212.
  • Hu C, Torres IJ, Qian H, Wong H, Halli P, Dhanoa T, Ahn S, Wang G, Bond DJ, Lam RW, Yatham LN. Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J Affect Disord.  2017;208:291-297.
  • Bond DJ, Silveira LE, MacMillan E, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN. Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. Br J Psych.  2016;208:146-52.
  • Bond DJ, Andreazza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, Young LT, Lam RW, Yatham LN. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology.  2016;65:76-83.
  • Satzer D, Bond DJ. Mania secondary to focal brain lesions: implications for understanding the functional neuroanatomy of bipolar disorder. Bipolar Disord.  2016;18:205-220.
  • Kozicky JM, McGirr A, Bond DJ, Gonzalez M, Silveira LE, Keramatian K, Torres IJ, Lam RW, Yatham LN. Neuroprogression and episode recurrence in bipolar I disorder: a study of grey matter volume changes in first episode mania and association with clinical outcome. Bipolar Disord.  2016;18:511-519.
  • Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant’Anna M, Kapczinski F, Lafer B, Sharma V, Parikh S, Daigneault A, Qian H, Bond DJ, Silverstone P, Walji N, Milev R, Baruch P, da Cunha A, Quevedo J, Dias R, Kunz M, Young LT, Lam RW, Wong H.. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double blind trial. Mol Psychiatry.  2016;21:1050-6
  • McElroy SL, Crow S, Blom TJ, Biernacka JM, Winham SJ, Geske J, Cuellar-Barboza AB, Bobo WV, Prieto ML, Veldic M, Mori N, Seymour LR, Bond DJ, Frye MA. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. J Affect Disord. 2016;191:216-21
  • McElroy SL, Crow S, Blom TJ, Cuellar-Barboza AB, Prieto ML, Veldic M, Winham SJ, Bobo WV, Geske J, Seymour LR, Mori N, Bond DJ, Biernacka JM, Frye MA. Clinical features of bipolar spectrum with binge eating behavior. J Affect Disord.  2016;201:95-98.